Lancet Infectious Diseases

Article	Citations
Infectious disease surveillance update	1561
Margaret Keller	1184
Research in brief	875
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	792
DNDi receives Dutch funding boost	659
Infectious disease surveillance update	649
Annelies Zinkernagel—Current ESCMID President	590
Increased choices of pneumococcal vaccines for policy makers	586
Pragmatic trials to inform policy decisions and planning	470
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	437
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	433
Reflecting on lessons from the 2014–16 Ebola virus outbreak	364
Sharing the road during the COVID-19 pandemic	364
DREAMS celebrates 10 years and looks to the future	352
Dengue: a hidden threat in blood transfusions amidst Brazil's largest outbreak?	348
Diane Edmund Griffin	337
Global health and pandemic preparedness at a crossroads	308
Using big data and mobile health to manage diarrhoeal disease in children in low-income and middle-income countries: societal barriers and ethical implications	306
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development	301
Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis	272
Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3	266
Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data	262
Development of the Mycetoma Activity and Severity clinical Scale (MASS): an international Delphi study	256
Correction to Lancet Infect Dis 2024; 24: 1045–58	254
Sipavibart: when a success changes into a failure	252

Inactivated COVID-19 vaccines to make a global impact	248
Reducing public health risks associated with wet markets	246
Tuberculosis services disrupted by war in Ukraine	239
Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literature	235
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals	232
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2023	231
Carissa Etienne	229
Peer review at The Lancet Infectious Diseases in 2023	213
The next chapter for Africa's genomic initiatives	212
Looking beyond the individual	205
Adaora “Ada” Alise Adimora	203
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	200
Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better?	199
Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics	197
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial	195
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac	193
Balancing adjunctive therapy for tuberculosis treatment	190
Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK	190
Endemic mycoses: geographical distribution is still a work in progress – Authors’ reply	188
The replenishment of the Global Fund	183
Global alliance to tackle HIV in children	183
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India	173
Wolfgang Preiser—co-discoverer of SARS-CoV-2 variants	172
Introducing our cover artist for 2025: Lillian Li	168
Maria Eugenia Toledo-Romani—doing a lot with the least	161
Engaging pose and gaze in global health research	160
Patrick de Marie Katoto—championing African public health	158
Persistence of Oropouche virus in body fluids among imported cases in France, 2024	157
Vaccination in Africa—no hesitancy without access	157
WHO reports gaps in global IPC programmes	153
Additional questions regarding transfusion-transmitted dengue virus in Brazil – Authors' reply	152
Infectious disease surveillance update	152
MMV533, a promising new antimalarial on the horizon	150
Expanding seasonal malaria chemoprevention beyond the Sahel region	148
Research in brief	146
14th Neglected Tropical Disease NGO Network conference	143
Nipah virus: an ever-present threat	143
Research in brief	141
Effectiveness of rotavirus vaccine in preventing transmission of rotavirus from children to household contacts in Malawi	139
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran	137
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran – Authors' reply	136
The persistence of HIV stigma in Kenya	135
Vanishing evidence of the non-blanching rash?	135
World Microbe Forum 2021	135
COVID-19 vaccination protects children and adolescents	134
Time for noma to enter the global health stage	133
Entering a labyrinth of COVID-19 stories	133
Crisis as a political ally: the unexpected power of AIDS	133
UK guidelines and testing for invasive meningococcal disease	133
Rajendra Kapila	132

The eternal cycle of pandemics	129
Old politics in pandemic management	127
Khorshed Pavri	126
Pandemic diaries under the lens	126
Triage of patients with Ebola virus disease	126
Updates on management of STIs	124
Strengthening the maternal and child health responses to Ebola outbreaks in Uganda	124
Promoting diversity and equity in publishing	124
IDWeek 2022	123
Buddha Basnyat—tackling typhoid and other infections in Nepal	122
Placing in-vitro heteroresistance in the context of clinical results	121
Infectious diseases surveillance update	121
Dengue outbreak in Peru affects adults and children	121
Research in brief	120
Risk of omicron infection for high-risk older adults in long-term care facilities	118
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	118
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases	117
Infectious disease surveillance update	117
Research in brief	117
COVID-19 vaccine: what are we doing and what should we do?	117
Chronicling PEPFAR's work in Africa	116
Tackling the politicisation of COVID-19 data reporting through open access data sharing	115
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?	115
The wrongful indictment of pre-referral rectal artesunate further delays the roll-out of this lifesaving drug	113
Time to redefine a primary vaccination series?	113
The superiority of bivalent over monovalent booster vaccines	112
Dengue fever: working towards global control considering biological, social, and planetary determinants	112
Laos eliminates lymphatic filariasis	109
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	108
Role of the G20 in safe reopening of international travel	108
What is the role of science academies in Africa?	108
COVID-19 in the MENA region	103
Adjuvantation helps to optimise COVID-19 vaccine candidate	102
Karamojong people embrace malaria chemoprevention	102
Minoarisoa Rajerison—fighting plague in Madagascar	101
Treating carbapenem-resistant Acinetobacter baumannii infections	100
The incalculable debts of South Africa's gold mines	98
Questioning bedaquiline availability	97
Infectious disease surveillance update	96
BCG: new life for a centenarian vaccine	95
A new network for pathogen surveillance	93
Infectious disease surveillance update	92
Bell's palsy and SARS-CoV-2 vaccines—an unfolding story – Authors' reply	88
Chickenpox vaccination recommended in the UK	87
Highlights from ASTMH 2023	87
COVID-19 and sexual health rights in Africa	86
High-Level Meeting on Antimicrobial Resistance 2024	86
Nathan Lo—translating infectious disease models into policy	86
Boosting immunity to protect from tickborne Lyme disease	86
Rare presentation of rapidly progressive tertiary syphilis in AIDS: a case report of syphilitic gumma	85
Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV	83
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	83
Desideratum: a developmentalist view of Zika virus infection	83
Revaccination with BCG: does it work?	82
Protein-based vaccine as the booster dose for adults: evidence and beyond	80
Excess mortality from COVID-19 in an English sentinel network population	80
Health-care provision for displaced populations arriving from Ukraine	80
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply	80
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	79
Updated criteria for paediatric sepsis and septic shock	78
A glimmer of hope beyond the spring for Europe	78
Surge of cutaneous leishmaniasis in Pakistan	78
Doxycycline PEP for prevention of STIs	78
Research in brief	78
Behind Cuba's successful pandemic response	77
A new global health hub in Germany	77
Hecolin vaccination strategies for hepatitis E outbreak control in resource-constrained settings	77
A patient with secondary syphilis following incomplete treatment of primary infection	77
Repurposing antibiotics to treat syphilis	77
Antibiotic de-escalation: finally, some action and not only words	77
Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control	75
Environment and infectious diseases	74
Mobile laboratory donations to African countries	74
COVID-19 in South Asia	73
The role of chemoprophylaxis in eliminating forest malaria and preventing simian malaria in humans	73
Two pandemics, a shared lesson	73
Serious threat of antimicrobial resistance in Ukraine	72
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	72
The promising prospects of a new yellow fever vaccine	72
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-co	72

Infectious disease surveillance update	72
Local communities	71
Albendazole and ivermectin co-formulation for soil-transmitted helminthiases	71
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	71
Ordinary people in extraordinary times	69
Emerging SARS-CoV-2 variants: shooting the messenger	69
Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy	69
Infectious diseases compensation in the USA: the relative value	69
Timing is everything when it comes to pertussis vaccination	68
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	67
Survival sex: “I have no option left”	67
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical t	67
Understanding the drivers of transmission of SARS-CoV-2	67
Evolving ethics of COVID-19 challenge trials	66
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach	66
Attention to skin-related neglected tropical diseases	66
The first reactive vaccination campaign against hepatitis E	66
Mass doses of fractional pneumococcal vaccine in humanitarian settings	66
Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19	65
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	65
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study	65
Potential for improvement in governance and national action plans to overcome antimicrobial resistance	65
Unveiling the viral aetiologies of lower respiratory infections	64
Leveraging the positives from the pandemic to strengthen infectious disease care in low-income and middle-income countries	64
Rapid diagnostic tests for Lassa fever: what do we aim for?	64
Barriers and enablers to implementing tuberculosis control strategies in EU and European Economic Area countries: a systematic review	64
Correction to Lancet Infect Dis 2022; 22: 265–73	63
The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunolog	63
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	63
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phas	63
Where are the long COVID trials?	63
Is the next generation of mosquito nets surviving expectations?	62
WHO's 2024 guidelines to combat hepatitis B	62
Threat of HIV and tuberculosis drug resistance after US funding cuts	62
Research in brief	61
The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children	61
A step forward in the journey towards hookworm vaccines	61
The Enhanced Gonococcal Surveillance Programme, Cambodia	61
Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode	60
Listeria monocytogenes: a rare, deadly cause of peritonitis	60
Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis	60
Engaging pharmacists and medicine vendors in antimicrobial stewardship in LMICs	60
New project to tackle visceral leishmaniasis in Kenya	60
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	60
COVID-19 pandemic more than a century after the Spanish flu	60
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	59
Prevention of long COVID: progress and challenges	59
Improving measurement of tuberculosis care cascades to enhance people-centred care	59
Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study	58
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe	58
Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial	58
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	58
Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival	58
Optimising vaccine immunogenicity in ageing populations: key strategies	58
Oriol Mitja—the beginning of the end for yaws	58
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies	58
Why development of outbreak analytics tools should be valued, supported, and funded	57
Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study	57
Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection	57
Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial	57
Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies – Authors' reply	57
The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinica	56
A case of SARS-CoV-2 reinfection in Ecuador	56
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy	56
Sexually acquired enteric infections among men who have sex with men	56
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial	56
Implications of bedaquiline-resistant tuberculosis	56
Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK	55
Limitations of using mobile phone data to model COVID-19 transmission in the USA	55
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity	54
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study	54
The interplay between COVID-19 restrictions and vaccination	54
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3	54
SARS-CoV-2 incidence and vaccine escape	53
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases – Authors' reply	53
A public health ethic should inform policies on COVID-19 immunity passports – Authors' reply	53
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	53
Bold measures to accelerate malaria elimination	52
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study	52
Can the USA return to pre-COVID-19 normal by July 4?	52
Is oropharyngeal sampling a reliable test to detect SARS-CoV-2?	51
Post-acute conditions of patients with COVID-19 not requiring hospital admission	51
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati	51
Adjunctive clindamycin therapy in invasive β-haemolytic streptococcal infections – Authors' reply	51
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	51
Sexually transmitted outbreaks and genomic surveillance	50
Discordant results of tests for tuberculosis reconsidered – Authors' reply	50
How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?	50
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a c	50
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages	49
Transitioning to endemicity with COVID-19 research	49
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial	49
John Sever	49
International platform trials: as diseases cross borders, so should trials	49
Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study	49